DXVX Secures Best-in-Class Preclinical Results for Oral Obesity Treatment

DXVX announced on May 12, 2025, that its oral obesity treatment (Oral GLP-1 Receptor Agonist) demonstrated outstanding pharmacokinetic (PK) results in preclinical animal studies. With these results, DXVX has secured the potential to develop a best-in-class new drug for obesity treatment through its in-house R&D efforts.

According to DXVX, recent animal studies on its oral obesity treatment candidate showed that the safety and efficacy indicators in pharmacokinetic tests were significantly superior to those of candidate substances currently being developed by global pharmaceutical companies.

In particular, the oral administration pharmacokinetic tests showed that the AUC (Area Under Curve), T1/2 (half-life), Cmax (maximum blood concentration), and Tmax (time to reach maximum concentration)?all indicators of absorption and retention in the body?were superior to those of global competitors. The company also confirmed that the initial blood concentration of the drug after administration increased much more gradually, reducing safety concerns related to rapid drug administration.

Currently, the most advanced substance in the global oral obesity treatment field is Orfoglipron, which has completed global Phase 3 clinical trials and entered the approval stage. Orfoglipron is based on the same organic synthetic chemical structure as the oral obesity treatment being developed by DXVX. In contrast, Danuglipron, which was in Phase 2 clinical trials, was recently discontinued by the global pharmaceutical company developing it.

Given this, with Orfoglipron expected to be the first to enter the market, DXVX described its latest preclinical results as highly encouraging.

DXVX is rapidly advancing further research and development, while also continuing discussions for early licensing out. The company is currently receiving term sheets and negotiating with several domestic and international companies.

A DXVX representative stated, "We will complete the preclinical trials of our candidate substance as soon as possible to quickly move into the IND stage. As we have already secured results that make early licensing out at the preclinical stage fully feasible, we will do our utmost to achieve our goals."

Meanwhile, a recent case in China saw Hansoh Pharmaceutical's oral obesity treatment licensed out to Merck for 2.9 trillion KRW after the completion of preclinical trials.

This content was produced with the assistance of AI translation services.